Eiseki Usami

Eiseki Usami

Auto-generated profile, based on publicly available information

Eiseki Usami

Department of Pharmacy, Ogaki Municipal Hospital, Ogaki, Gifu, Japan

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2014 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
EUEiseki Usami
Eiseki Usami
MKMichio Kimura
Michio Kimura
TKTetsufumi Kanematsu
Tetsufumi Kanematsu
SYShinya Yoshida
Shinya Yoshida
TMTakayuki Mori
Takayuki Mori
HTHitomi Teramachi
Hitomi Teramachi
Patients prescribed liposomal‑amphotericin B (L‑AMB) frequently require supplemental potassium to prevent hypokalemia. The aim of this retrospective study was to examine the appropriate potassium supplementation conditions to treat hypokalemia induced by L‑AMB. The subjects were 100 hematological patients who received L‑AMB for the first time between April 2012 and March 2013. A total of seven patients were excluded. Of the remaining 93 patients, 48 (51.6%) were assigned to the group receiving supplemental potassium (supplementation group), and 45 (48.4%) were assigned to the group without potassium supplementation (non‑supplementation group). Hypokalemia greater than grade 3 was exhibited by 50 of the 93 (53.8%) patients. Multivariate analysis revealed that the minimum serum potassium levels during L‑AMB administration (≤2.98 mEq/l) were an independent factor significantly contributing to the effectiveness of potassium supplementation [odds ratio (OR), 3.62; 95% confidence interval (CI), 1.44‑9.59; P<0.01]. In addition, multivariate analysis revealed that the serum potassium levels (≥2.83 mEq/l) prior to the potassium supplementation were an independent factor significantly contributing to the development of proper potassium supplementation (OR, 14.21; 95% CI, 1.95‑310.72; P=0.02), and no significant difference was observed in the dosage of the potassium supplementation administered to the patients who recovered from hypokalemia and those who did not. In conclusion, it is necessary to begin potassium supplementation prior to the reduction of the serum potassium levels to <2.83 mEq/l. Potassium supplementation at an early stage of L‑AMB treatment is important to prevent severe electrolyte abnormalities.

23 December 2023 in American Journal of Infection Control
Verified
Journal Article
Closed access
KOKengo Ohashi
Kengo Ohashi
TMTomoko Matsuoka
Tomoko Matsuoka
YSYasutaka Shinoda
Yasutaka Shinoda
TTTakamasa Takahashi
Takamasa Takahashi
HSHiroaki Shikano
Hiroaki Shikano
EUEiseki Usami
Eiseki Usami

7 November 2023 in Medicina
Verified
Journal Article
Open access
PDF file
HAHiroki Asano
Hiroki Asano
Yoshihiro noguchiYoshihiro noguchi
Yoshihiro noguchi
MKMichio Kimura
Michio Kimura
EUEiseki Usami
Eiseki Usami
TYTomoaki Yoshimura
Tomoaki Yoshimura
Background and Objectives: One type of immune-related adverse event caused by immune checkpoint inhibitors (ICIs) is pituitary-related adverse events. The management of pituitary-related adverse events is important because they can be fatal if not treated promptly. Therefore, this study was conducted to investigate the onset of pituitary-related adverse events using the Japanese Adverse Drug Report (JADER) database. Materials and Methods: Cases registered in the JADER database from 2004 to 2019 were used. The target drugs were ipilimumab, nivolumab, pembrolizumab, avelumab, atezolizumab, and durvalumab, and the target adverse events were the high-level terms “Anterior pituitary hypofunction,” “Anterior pituitary hyperfunction,” “Posterior pituitary disorder,” and “Pituitary neoplasm” in the Medical Dictionary for Regulatory Activities, Japanese version (MedDRA/J). The information component (IC) was used for signal detection and IC delta (ICΔ) was used for women-related signals. Onset timing and patterns were analyzed using the Weibull distribution. Results: Signals were detected with ipilimumab, nivolumab, pembrolizumab, and atezolizumab in “Anterior pituitary hypofunction,” with ICs and 95% credible intervals (95%CrI) of 5.53 (5.30–5.69), 4.96 (4.79–5.08), 4.04 (3.76–4.25), and 2.40 (1.53–3.00). Significant signals were detected in women, except for atezolizumab. Additionally, the time of onset was classified as the wear-out failure type. Inverse signals were detected with ipilimumab and nivolumab in “Posterior pituitary disorder,” with ICs (95%CrI) of −1.24 (−2.80–−0.26), and −0.89 (−1.64–−0.37). Conclusions: Anterior pituitary hypofunction is likely to occur with the long-term administration of ipilimumab, nivolumab, and pembrolizumab. Further investigation is needed to determine the differences in the tendencies to detect signals in the anterior and posterior pituitaries between ipilimumab and nivolumab.

28 April 2017 in Molecular and Clinical Oncology
Verified
Journal Article
Open access
PDF file
EUEiseki Usami
Eiseki Usami
MKMichio Kimura
Michio Kimura
MIMina Iwai
Mina Iwai
HTHitomi Teramachi
Hitomi Teramachi
TYTomoaki Yoshimura
Tomoaki Yoshimura
The purpose of this study was to assess the incidence of tumor lysis syndrome (TLS) in patients with hematological malignancies treated with rasburicase, and to evaluate the dose and duration of rasburicase administration. A total of 52 patients were enrolled. The background of the patients, incidence of TLS and laboratory data were retrospectively examined; in addition, the dose and duration of rasburicase administration and the factors affecting the onset of TLS were evaluated and compared among TLS risk categories. During the study period, 2 (3.8%) of the patients developed clinical TLS and 24 (46.2%) developed laboratory TLS (LTLS). Although the LTLS rate was very high, there were no life-threatening cases of TLS. The median daily dose of rasburicase administered to all patients was 7.5 mg/day (interquartile range, 7.5–9.0 mg/day), and the daily weight-based dose was 0.147 mg/kg/day (range, 0.126–0.178 mg/kg/day). The administration duration was 3 days (interquartile range, 3–4 days). Additionally, there was no significant association between TLS risk classification and daily rasburicase administration dose, duration, or post-administration laboratory data. The factors affecting the onset of TLS included serum uric acid level, as well as serum creatinine and phosphate levels. Rasburicase was highly effective in the prevention and management of hyperuricemia, even at a low-dose (7.5 mg/day) and a duration that was 3 days shorter compared with that recommended by the manufacturer. Therefore, clinicians should administer rasburicase based on their clinical judgment, taking into consideration the cost-effectiveness of this therapy.

27 November 2018 in Molecular and Clinical Oncology
Verified
Journal Article
Open access
PDF file
EUEiseki Usami
Eiseki Usami
MKMichio Kimura
Michio Kimura
STShoya Takenaka
Shoya Takenaka
MIMina Iwai
Mina Iwai
HTHitomi Teramachi
Hitomi Teramachi
TYTomoaki Yoshimura
Tomoaki Yoshimura
Pomalidomide (POM) is a second‑generation immunomodulatory agent with proven efficacy in patients with relapsed/refractory multiple myeloma (RRMM) proven to be refractory to previous treatment with lenalidomide (LEN) and bortezomib. We herein conducted a retrospective analysis of 14 RRMM patients receiving POM to determine its tolerability and safety in the clinical setting. The median age of the patients was 72 years (range, 58‑84 years), and 85.7% of the patients were aged >70 years. The most frequent treatment dose was 3 mg/day. POM dose reductions were required in 54.5% (6/11) of the patients. The patient data were compared among three age groups (75 years) and there was only significant difference in daily POM treatment dose. The tolerability of POM must be confirmed, particularly in elderly patients. Dose reduction from 4 to 3 mg occurred during the second cycle in 83.3% (5/6) of the patients. It is important to determine the tolerability of POM in the early phases of treatment. The most frequently reported grade 3/4 hematological adverse events were neutropenia (64.3%), anemia (64.3%) and thrombocytopenia (57.1%). Although the median number of treatment cycles was 4 (range, 1‑13), 21.4% (3/14) of the patients with a performance status (PS) of 3 were administered only 1 treatment cycle. The tolerability of POM was low among patients with poor PS and an aggressive treatment introduction should be avoided. However, 21.4% (3/14) of the patients were able to continue treatment for >1 year and some patients received long‑term therapy. POM does not require dose modification for renal function, and multiple capsule doses are available, which is an advantage of POM compared with LEN. POM may be administered to late‑stage RRMM patients in a real‑world clinical setting, but elderly patients or those with poor PS must be treated with caution. In this manner, the treatment options for RRMM patients may be expanded by assessing the tolerability and safety of POM.

1 May 2021
Verified
Journal Article
Closed access
TFT Fukuoka
T Fukuoka
YYYoshihiro Yamamoto
Yoshihiro Yamamoto
JUJ Utsunomiya
J Utsunomiya
EUE Usami
E Usami
MKM Kimura
M Kimura
YTY Toda
Y Toda